Scilex Holding Company to Present Oral, Poster Presentations and Symposia on ZTlido (lidocaine topical system) at the 2024 Annual PAINWeek Conference in Las Vegas, NV on September 3-5, 2024

Core Viewpoint - Scilex Holding Company is actively participating in the 2024 Annual PAINWeek conference to present its non-opioid pain management product, ZTlido, highlighting its significance in addressing unmet needs in pain management [1][2]. Company Overview - Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain [4][6]. - The company’s commercial products include ZTlido (lidocaine topical system) 1.8%, ELYXYB (oral solution for migraine treatment), and Gloperba (liquid oral colchicine for gout) [4][5]. Product Presentations - ZTlido will be featured in several presentations at the PAINWeek conference, including a session on optimizing gabapentinoids for neuropathic pain and analyses on decreased opioid and cost utilization compared to traditional lidocaine patches [2]. Research and Development - Scilex has three product candidates in development: SP-102 (dexamethasone gel for sciatica), SP-103 (next-generation lidocaine topical system), and SP-104 (low-dose naltrexone for fibromyalgia) [5]. - SP-102 has completed a Phase 3 study and received Fast Track status from the FDA, while SP-103 has recently completed a Phase 2 trial [5]. Market Positioning - The company targets high unmet needs in pain management, positioning itself to capitalize on large market opportunities with its non-opioid therapies [4].